Viewing Study NCT06253650


Ignite Creation Date: 2025-12-24 @ 5:19 PM
Ignite Modification Date: 2025-12-31 @ 7:50 AM
Study NCT ID: NCT06253650
Status: RECRUITING
Last Update Posted: 2024-06-13
First Post: 2024-02-02
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease
Sponsor: Gruppo Oncologico del Nord-Ovest
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module